Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of NT 201 (Xeomin) in Cervical Dystonia
NCT00541905Phase 4Completed
- Sponsor
- Merz
- Start
- Sep 2007
- Primary completion
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of incobotulinumtoxinA in cervical dystonia (CD), sponsored by Merz. Primary endpoint: Toronto Western Spasmodic Torticollis Rating Scale Total Score at 4 weeks. Started Sep 2007; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT00541905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541905.